TNSN07087A1 - Stable liquid formulations of plasmid dna - Google Patents

Stable liquid formulations of plasmid dna

Info

Publication number
TNSN07087A1
TNSN07087A1 TNP2007000087A TNSN07087A TNSN07087A1 TN SN07087 A1 TNSN07087 A1 TN SN07087A1 TN P2007000087 A TNP2007000087 A TN P2007000087A TN SN07087 A TNSN07087 A TN SN07087A TN SN07087 A1 TNSN07087 A1 TN SN07087A1
Authority
TN
Tunisia
Prior art keywords
plasmid dna
plasmid
liquid formulations
dna
stable
Prior art date
Application number
TNP2007000087A
Other languages
English (en)
Inventor
Francis Blanche
Michel Couder
Nicolas Maestrali
Thierry Guillemin
David Gaillac
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of TNSN07087A1 publication Critical patent/TNSN07087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TNP2007000087A 2005-09-19 2007-03-08 Stable liquid formulations of plasmid dna TNSN07087A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
TNSN07087A1 true TNSN07087A1 (en) 2008-06-02

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000087A TNSN07087A1 (en) 2005-09-19 2007-03-08 Stable liquid formulations of plasmid dna

Country Status (14)

Country Link
EP (1) EP1791945A1 (ja)
JP (1) JP2008512997A (ja)
KR (1) KR20070058621A (ja)
CN (1) CN101040041A (ja)
AU (1) AU2005284244A1 (ja)
BR (1) BRPI0515553A (ja)
CA (1) CA2579340A1 (ja)
EA (1) EA011554B1 (ja)
IL (1) IL181753A0 (ja)
MX (1) MX2007003214A (ja)
NO (1) NO20071946L (ja)
NZ (1) NZ553914A (ja)
TN (1) TNSN07087A1 (ja)
WO (1) WO2006029908A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
EP3241903A4 (en) * 2014-12-29 2018-07-04 Bonac Corporation Composition containing nucleic acid molecule stably
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
CN110869501B (zh) * 2017-08-01 2023-08-18 深圳华大智造科技股份有限公司 一种高效的内切酶缓冲液体系
US11248257B2 (en) 2017-08-25 2022-02-15 Zoetis Services Llc Method of immobilizing a nucleic acid probe to a solid support
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
JP2021536241A (ja) * 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 核酸を検出する方法
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
KR20230141965A (ko) * 2022-03-24 2023-10-10 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
AU782193B2 (en) * 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef

Also Published As

Publication number Publication date
EA200700656A1 (ru) 2007-10-26
BRPI0515553A (pt) 2008-07-29
MX2007003214A (es) 2007-10-11
CA2579340A1 (en) 2006-03-23
EA011554B1 (ru) 2009-04-28
AU2005284244A1 (en) 2006-03-23
JP2008512997A (ja) 2008-05-01
NO20071946L (no) 2007-05-29
NZ553914A (en) 2009-11-27
KR20070058621A (ko) 2007-06-08
EP1791945A1 (en) 2007-06-06
CN101040041A (zh) 2007-09-19
WO2006029908A1 (en) 2006-03-23
IL181753A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
TNSN07087A1 (en) Stable liquid formulations of plasmid dna
PH12015500549A1 (en) Hppd variants and methods of use
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2007035213A3 (en) Transgenic ungulates expressing ctla4-ig and uses thereof
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2004067753A3 (en) Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
MX2010014233A (es) Compuestos quimicos 251.
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2007022030A3 (en) Methods and compositions for the efficient delivery of therapeutic agents to cells and animals
IN2015DN02729A (ja)
WO2011026614A3 (en) Compositions and methods for disinfecting materials
GB201001602D0 (en) Oligopeptidic compounds and uses therof
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
BR112012016128A2 (pt) agente terapêutico (y-39983) para disfunção endotelial da córnea
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
TW200724679A (en) Treatment of disease using an improved regulated expression system
HUP0203469A2 (hu) Eljárások és eszközök növények kénvegyület-tartalmának növelésére
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
MX2007015127A (es) Oligonucleotidos estimuladores de la proliferacion de celulas madre mesenquimatosas y sus usos.
MY168692A (en) The treatment of viral infections